Drugs / RO7303359
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04615325 | Dec 2020 → Jan 2023 | diffuse secondary choroid atrophy | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7303359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04615325 ↗ |
| Route | Intravitreal | “Patients received a single intravitreal (IVT) injection of RO7303359” PMID 40538770 ↗ Apr 2025 |
| Target | IL33 | “anti-IL-33 fragment antigen-binding region (Fab)” PMID 40538770 ↗ Apr 2025 |